{"entity":{"id":"nct06423937","kind":"trial","name":"Fruquintinib Plus Camrelizumab and HAIC in the Treatment of Non-MSI-H Advanced Colorectal Cancer","aka":[],"tldr":"A phase 2 trial of camrelizumab in colorectal cancer, run by Fudan University, not yet recruiting.","summary":"Fruquintinib Plus Camrelizumab and HAIC in the Treatment of Non-MSI-H Advanced Colorectal Cancer is a phase 2, interventional study registered as NCT06423937 by Fudan University, with a registry enrolment figure of 129 participants, started 2024-05 and due to reach its primary completion in 2026-07. Interventions recorded: combination therapy Combination: Fruquintinib plus Camrelizumab and HAIC (TOMOX/TOMIRI) Maintenance: Fruquintinib plus Camrelizumab. Conditions listed: Colorectal Cancer. Primary outcome: objective response rate (ORR). Colorectal eligibility wording from the registry: \"* Patients with histologically or cytologically confirmed non-MSI-H ( according to the detection criteria of the institutional testing center, immunohistochemistry, PCR or NGS detection can be used ) unresectable advanced colorectal cancer with liver metastasis ;\". Sites: China. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06423937","url":"https://clinicaltrials.gov/study/NCT06423937"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer","msi-high-colorectal"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["camrelizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06423937","phase":"2","setting":"A Single-center, Open-label, Double-cohort Clinical Study of Fruquintinib Plus Camrelizumab Plus HAIC in the Treatment of Non-MSI-H Advanced Colorectal Cancer Patients With Liver Metastasis After the Failure of First-line Treatment","sponsor":"Fudan University","participation":[{"nct":"NCT06423937","source":"https://clinicaltrials.gov/study/NCT06423937","fetchedAt":"2026-10-07T16:54:39.727Z","studySha256":"5aa574319c5dee75434b296e8114e8eb748cb5482f51b74d40ce4e0366bd0df8","overallStatus":"NOT_YET_RECRUITING","lastUpdatePosted":"2024-05-21","leadSponsor":"Fudan University","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"75 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":129,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":0,"countries":["China"]}],"started":"2024-05","startedType":"estimated","enrolled":129,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06423937/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"msi-high-colorectal","kind":"cancer","name":"Mismatch-repair deficient (MSI-high) colorectal cancer","route":"/cancers/msi-high-colorectal/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"camrelizumab","kind":"drug","name":"Camrelizumab","route":"/drugs/camrelizumab/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}